| 产品描述: | MRTX-1257 是一种有效的、选择性的、不可逆的、共价的和口服活性的 KRAS G12C 的抑制剂,可在H358细胞中抑制KRAS依赖性的ERK磷酸化,对应的IC50值为900 pM |
| 靶点: |
KRAS G12C; KRAS dependent ERK phosphorylation(in H358 cells):900 pM;Ras |
| 体外研究: |
MRTX1257 demonstrates rapid, irreversible modification of GDP-bound recombinant KRAS G12C and suppresses ERK phosphorylation with an IC50 = 1 nM in the H358 cell line. In proteomics studies designed to assess global protein modification, MRTX1257 is shown to be highly selective for the targeted Cys12 of KRAS G12C versus other surface-exposed cysteine residues in NCI-H358 cells |
| 体内研究: |
MRTX1257 exhibits 31% bioavailability in mouse, demonstrates near-complete inhibition of KRAS signaling in tumor tissue, and complete durable tumor regression in MIA PaCa-2 xenografts |
| 细胞实验: |
Cell lines: H358 Cells Concentrations: 1 μM Incubation Time: -- Method: -- |
| 动物实验: |
Animal Models: mice Dosages: 3 mg/kg, 30 mg/kg Administration: IV, Oral gavage |
| 参考文献: |
1. Matthew A. Marx, et al. Structure-Based Drug Discovery of MRTX1257, a Selective, Covalent KRAS G12C Inhibitor with Oral Activity in Animal Models of Cancer. MIRATI THERAPLUTICS. 2. Matthew A. Marx, et al. Abstract B30: Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer. Mol Cancer Res 2020;18(5_Suppl):Abstract nr B30. |
| 溶解性: |
Soluble in DMSO、Ethanol |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.768 ml |
8.838 ml |
17.677 ml |
| 5 mM |
0.354 ml |
1.768 ml |
3.535 ml |
| 10 mM |
0.177 ml |
0.884 ml |
1.768 ml |
| 50 mM |
0.035 ml |
0.177 ml |
0.354 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |